• 1
    Engel M., Hoffmann T., Wagner L., Wermann M., Heiser U., Kiefersauer R., Huber R., Bode W., Demuth H.U., Brandstetter H. (2003) The crystal structure of dipeptidyl peptidase IV (CD26) reveals its functional regulation and enzymatic mechanism. Proc Natl Acad Sci USA;100:50635068.
  • 2
    Rasmussen H.B., Branner S., Wiberg F.C., Wagtmann N. (2003) Crystal structure of human dipeptidyl peptidase IV/CD26 in complex with a substrate analog. Nat Struct Biol;10:1925.
  • 3
    Zander M., Madsbad S., Madsen J.L., Holst J.J. (2002) Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. Lancet;359:824830.
  • 4
    Pospisilik J.A., Stafford S.G., Demuth H.U., McIntosh C.H., Pederson R.A. (2002) Long-term treatment with dipeptidyl peptidase IV inhibitor improves hepatic and peripheral insulin sensitivity in the VDF Zucker rat: a euglycemic-hyperinsulinemic clamp study. Diabetes;51:26772683.
  • 5
    Pratley R.E., Salsali A. (2007) Inhibition of DPP-4: a new therapeutic approach for the treatment of type 2 diabetes. Curr Med Res Opin;23:919931.
  • 6
    Aertgeerts K., Ye S., Tennant M.G., Kraus M.L., Rogers J., Sang B.C., Skene R.J., Webb D.R., Prasad G.S. (2004) Crystal structure of human dipeptidyl peptidase IV in complex with a decapeptide reveals details on substrate specificity and tetrahedral intermediate formation. Protein Sci;13:412421.
  • 7
    Gorrell M.D. (2005) Dipeptidyl peptidase IV and related enzymes in cell biology and liver disorders. Clin Sci;108:277292.
  • 8
    Flatt P.R., Bailey C.J., Green B.D. (2008) Dipeptidyl peptidase IV (DPP IV) and related molecules in type 2 diabetes. Front Biosci;13:36483660.
  • 9
    Kim D., Wang L., Beconi M., Eiermann G.J., Fisher M.H., He H., Hickey G.J. et al. (2005) (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. J Med Chem;48:141151.
  • 10
    Todd J.F., Bloom S.R. (2007) Incretins and other peptides in the treatment of diabetes. Diabet Med;24:223232.
  • 11
    Karasik A., Aschner P., Katzeff H., Davies M.J., Stein P.P. (2008) Sitagliptin, a DPP-4 inhibitor for the treatment of patients with type 2 diabetes: a review of recent clinical trials. Curr Med Res Opin;24:489496.
  • 12
    Villhauer E.B., Brinkman J.A., Naderi G.B., Burkey B.F., Dunning B.E., Prasad K., Mangold B.L., Russell M.E., Hughes T.E. (2003) 1-[[(3-hydroxy-1-adamantyl)amino]acetyl]-2-cyano-(S)-pyrrolidine: a potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties. J Med Chem;46:27742789.
  • 13
    He Y.L., Sadler B.M., Sabo R., Balez S., Wang Y., Campestrini J., Laurent A., Ligueros-Saylan M., Howard D. (2007) The absolute oral bioavailability and population-based pharmacokinetic modelling of a novel dipeptidylpeptidase-IV inhibitor, vildagliptin, in healthy volunteers. Clin Pharmacokinet;46:787802.
  • 14
    Burkey B.F., Li X., Bolognese L., Balkan B., Mone M., Russell M., Hughes T.E., Wang P.R. (2005) Acute and chronic effects of the incretin enhancer vildagliptin in insulin-resistant rats. J Pharmacol Exp Ther;315:688695.
  • 15
    Augeri D.J., Robl J.A., Betebenner D.A., Magnin D.R., Khanna A., Robertson J.G., Wang A. et al. (2005) Discovery and preclinical profile of Saxagliptin (BMS-477118): a highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. J Med Chem;48:50255037.
  • 16
    Feng J., Zhang Z., Wallace M.B., Stafford J.A., Kaldor S.W., Kassel D.B., Navre M., Shi L., Skene R.J., Asakawa T., Takeuchi K., Xu R., Webb D.R., Gwaltney S.L. (2007) Discovery of alogliptin: a potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV. J Med Chem;50:22972300.
  • 17
    Eckhardt M., Langkopf E., Mark M., Tadayyon M., Thomas L., Nar H., Pfrengle W., Guth B., Lotz R., Sieger P., Fuchs H., Himmelsbach F. (2007) 8-(3-(R)-aminopiperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydropurine-2,6-dione (BI 1356), a highly potent, selective, long-acting, and orally bioavailable DPP-4 inhibitor for the treatment of type 2 diabetes. J Med Chem;50:64506453.
  • 18
    Qiao L., Baumann C.A., Crysler C.S., Ninan N.S., Abad M.C., Spurlino J.C., Desjarlais R.L. et al. (2006) Discovery, SAR, and X-ray structure of novel biaryl-based dipeptidyl peptidase IV inhibitors. Bioorg Med Chem Lett;16:123128.
  • 19
    Edmondson S.D., Mastracchio A., Beconi M., Colwell L.F. Jr, Habulihaz B., He H., Kumar S. et al. (2004) Potent and selective proline derived dipeptidyl peptidase IV inhibitors. Bioorg Med Chem Lett;14:51515155.
  • 20
    Ammirati M.J., Andrews K.M., Boyer D.D., Brodeur A.M., Danley D.E., Doran S.D., Hulin B. et al. (2009) (3,3-Difluoro-pyrrolidin-1-yl)-[(2S,4S)-(4-(4-pyrimidin-2-yl-piperazin-1-yl)-pyrrolidin-2-yl]-methanone: a potent, selective, orally active dipeptidyl peptidase IV inhibitor. Bioorg Med Chem Lett;19:19911995.
  • 21
    Lankas G.R., Leiting B., Roy R.S., Eiermann G.J., Beconi M.G., Biftu T., Chan C.C. et al. (2005) Dipeptidyl peptidase IV inhibition for the treatment of type 2 diabetes: potential importance of selectivity over dipeptidyl peptidases 8 and 9. Diabetes;54:29882994.
  • 22
    Nordhoff S., Cerezo-Gálvez S., Feurer A., Hill O., Matassa V.G., Metz G., Rummey C., Thiemann M., Edwards P.J. (2006) The reversed binding of beta-phenethylamine inhibitors of DPP-IV: X-ray structures and properties of novel fragment and elaborated inhibitors. Bioorg Med Chem Lett;16:17441748.
  • 23
    Friesner R.A., Banks J.L., Murphy R.B., Halgren T.A., Klicic J.J., Mainz D.T., Repasky M.P., Knoll E.H., Shelley M., Perry J.K., Shaw D.E., Francis P., Shenkin P.S. (2004) Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J Med Chem;47:17391749.